JUV 191
Alternative Names: JUV-191Latest Information Update: 24 Nov 2023
At a glance
- Originator Juvena Therapeutics
- Class Proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Obesity
Highest Development Phases
- Research Obesity
Most Recent Events
- 20 Oct 2023 JUV 191 is available for licensing as of 20 Oct 2023. https://www.juvenatherapeutics.com/our-science/
- 20 Oct 2023 Juvena Therapeutics has patent pending for drug discovery and development platform in USA, prior to October 2023(Juvena Therapeutics pipeline, October 2023)
- 20 Oct 2023 Early research in Obesity in USA (unspecified route) (Juvena Therapeutics pipeline, October 2023)